Outcomes of Patients with Sarcoma and COVID-19 Infection: A Single Institution Cohort Analysis

Abstract

Outcomes for patients (pts) with sarcoma and COVID-19 are unknown. This is a single institution retrospective study of adults with sarcoma and COVID-19. Ten pts [median age 60 (range 24–69)] were identified. Five were hospitalized; two died from COVID-19 complications; another died from sarcoma. Time between last systemic treatment dose and COVID-19 diagnosis was 6–41 days in pts who died. 5 underwent prior radiation (RT); time between RT and COVID-19 diagnosis was 20–62 days for pts who died. All three pts with WBC differential data (two died) were lymphopenic. Efforts to capture outcomes for a larger cohort are urgently needed.

Keywords:

• Sarcoma
• COVID-19
• cohort Study

Previous presentation

A portion of the data was accepted for presentation on November 18, 2020 at the virtual annual meeting of the Connective Tissue Oncology Society.

Disclosure statement

MJW: Advisory role with Tempus, Deciphera, Adaptimmune. Research funding to institution from Athenex, Deciphera, Incyte, Tempus, Adaptimmune, GSK.

SMP: Consulting, honoraria and advisory activity with Glaxo Smith Kline, Eli Lilly, Seattle Genetics, Bayer, Tempus, Daiichi Sankyo and Blueprint Medicine. Research funding to institution from Merck, EMD Serono, Incyte, Presage, Janssen, Oncosec and Juno.

LDC: Honoraria or has served on advisory boards for BluePrint Medicines and Regeneron. Research funding to institution from Eli Lilly, AADi, BluePrint Medicine, Iterion, Gradalis, Philogen, Advenchen Laboratories, and CBA Pharma.

GHL: Consulting or Advisor Role with G1 Therapeutics,Partners, Spectrum, Invitae, Sandoz, Samsung,Beyond Spring. Research Funding from Amgen

NMK: Consulting or Advisory Role with Celldex, BMS, Beyond Springs, Invitae, Total Health, Janssen, Spectrum Pharmaceuticals, Bayer. Travel/Accommodations from Bayer, Mylan, Janssen, Agendia, Spectrum Pharmaceuticals

PG: Consulting for AstraZeneca, Bayer, Bristol-Myers Squibb, Clovis Oncology, Driver, EMD Serono, Exelixis, Foundation Medicine, GlaxoSmithKline, Genentech, Genzyme, Heron Therapeutics, Janssen, Merck, Mirati Therapeutics, Pfizer, Roche, Seattle Genetics, QED Therapeutics; participation in educational program for Bristol-Myers Squibb; and institutional research funding from AstraZeneca, Bavarian Nordic, Bayer, Bristol-Myers Squibb, Clovis Oncology, Debiopharm, Genentech, GlaxoSmithKline, Immunomedics, Kure It Cancer Research, Merck, Mirati Therapeutics, Oncogenex, Pfizer, QED Therapeutics.

ETL: Institutional support from Springworks and Daiichi.

SM, SW, MJT, ARK, MMM: No conflicts of interest to declare.